QC
NKTR icon

Quantessence Capital’s Nektar Therapeutics NKTR Stock Holding History

Quantessence Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,645
Closed -$223K – 267
2025
Q2 		$223K Buy
+8,645
New +$97.1K 0.07% 158

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Quantessence Capital's NKTR Position: Q3 2025 in Review

Quantessence Capital sold out of Nektar Therapeutics (NKTR) in Q3 2025, closing a stake of 8,645 shares — an estimated $223K sold.

Quantessence Capital first reported a position in NKTR in Q2 2025 and held it in 1 quarter. The position peaked at $223K in Q2 2025. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • Quantessence Capital reported no remaining Nektar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quantessence Capital sold 8,645 Nektar Therapeutics shares in Q3 2025, an estimated $223K.
  • Quantessence Capital first reported a position in Nektar Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quantessence Capital's Nektar Therapeutics position peaked at $223K in Q2 2025.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Quantessence Capital's 13F filing for Q3 2025, filed 14 Nov 2025.